Search research articles
Contact Us
Filters
Showing results (151-160 of 169) with videos related to
Page
of 17
Sort By:
ESMO Open
|
June 5, 2024
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B
F Marmé, M Martin, M Untch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 20, 2022
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]
S Loibl, M Untch, N Burchardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S Loibl, M Untch, N Burchardi, et al.
ESMO Open
|
November 30, 2025
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival
J Crown, D Stroyakovskii, D A Yardley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2020
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
P A Fasching, T Link, J Hauke, et al.
ESMO Open
|
April 25, 2024
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
P Meyer-Wilmes, J Huober, M Untch, et al.
Geburtshilfe Und Frauenheilkunde
|
July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
M Untch, N Harbeck, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2020
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
T Karn, C Denkert, K E Weber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 26, 2025
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy-PENELOPE-B
S Loibl, M Martin, H Bonnefoi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2015
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel
P Hadji, R E Coleman, C Wilson, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 169) with videos related to
Sort By:
Page
of 17
ESMO Open
|
June 5, 2024
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B
F Marmé, M Martin, M Untch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 20, 2022
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]
S Loibl, M Untch, N Burchardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S Loibl, M Untch, N Burchardi, et al.
ESMO Open
|
November 30, 2025
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival
J Crown, D Stroyakovskii, D A Yardley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2020
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
P A Fasching, T Link, J Hauke, et al.
ESMO Open
|
April 25, 2024
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
P Meyer-Wilmes, J Huober, M Untch, et al.
Geburtshilfe Und Frauenheilkunde
|
July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
M Untch, N Harbeck, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2020
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
T Karn, C Denkert, K E Weber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 26, 2025
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy-PENELOPE-B
S Loibl, M Martin, H Bonnefoi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2015
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel
P Hadji, R E Coleman, C Wilson, et al.
Page
of 17